Preclinical Assets Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

Which drivers are expected to have the greatest impact on the over the preclinical assets market's growth?
The expansion of the preclinical asset market is anticipated to be fuelled by the surge in drug discovery. Drug discovery is the identification process of potential medicinal agents through chemical substances. This process leads to the unearthing of possible new drugs. Preclinical assets carry significant weight during this procedure as they provide crucial data and proof, assisting in picking molecules ready for clinical testing. For instance, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based pharmaceutical sector representative, reported in June 2023 that there was considerable production growth in the European pharmaceutical industry. The figures escalated from $352.48 billion in 2021 to an impressive $369.95 billion in 2022. Consequently, the upswing in drug discovery is propelling the preclinical assets market's growth.

Get Your Preclinical Assets Market Report Here:
https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

What is the future CAGR of the preclinical assets market, and how will it impact industry expansion?
The market size for preclinical assets has seen a substantial increase in recent years. It is projected to rise from $5.87 billion in 2024 to $6.4 billion in 2025, boasting a compound annual growth rate (CAGR) of 9.1%. The growth witnessed in the past years is due to factors such as the demand for drug development, advancements in biotechnology, regulatory obligations, growth in research funding, and joint research initiatives.

The size of the preclinical assets market is projected to experience robust expansion in the forthcoming years, swelling to a valuation of $9.3 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.8%. This projected growth through the anticipated period is attributable to several factors such as precision medicine and individualized treatments, incorporation of artificial intelligence and machine learning, expansion of biobanking, emphasis on rare diseases, and government support and financing initiatives. Furthermore, the forecast period will likely see the rise of advanced imaging techniques, 3D organoid models, multi-omics integration, improved predictive models, automation and high throughput screening.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

How are the latest trends influencing the growth of the preclinical assets market?
The advent of product innovations is a critical trend gaining traction in the preclinical assets sector. Major corporations within this industry are working on the creation of novel products and solutions in a bid to solidify their standing and obtain a competitive edge. For example, in April 2022, Charles River Laboratories International - a U.S. pharmaceutical firm with specialisms in preclinical and clinical labs, collaborated with Valo Health Inc., an American tech firm dedicated to revolutionizing drug discovery, to introduce Logica, an AI-powered drug solution that effectively converts clients' biological insights into optimized preclinical assets. Logica employs Charles River's superior preclinical expertise and Valo's AI-enabled Opal Computational Platform to offer clients a revamped drug discovery process through one comprehensive offering that smoothly transitions targets to candidate nomination. By teaming up with Valo, Charles River blends its lab proficiency with molecular design technology, thereby bringing about industry revolution that provides clients with highly eligible leads and candidates while linking client costs to value generation.

Which key market segments comprise the preclinical assets market and drive its revenue growth?
The preclinical assets market covered in this report is segmented -

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:
1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development
2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing
3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support
4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations
5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

What regions are at the forefront of preclinical assets market expansion?
North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the preclinical assets market?
Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

What Is Covered In The Preclinical Assets Global Market Report?

• Market Size Forecast: Examine the preclinical assets market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the preclinical assets market for a structured understanding.
• Key Players Overview: Analyze major players in the preclinical assets market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the preclinical assets market.
• Segment Contributions: Evaluate how different segments drive overall growth in the preclinical assets market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the preclinical assets market.
• Industry Challenges: Identify potential risks and obstacles affecting the preclinical assets market.
• Competitive Landscape: Review strategic developments in the preclinical assets market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.